BIIB
USDBiogen Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$133.045
High
$134.590
Low
$132.370
Volume
1.14M
Company Fundamentals
Market Cap
19.7B
Industry
Drug Manufacturers - General
Country
United States
Trading Stats
Avg Volume
1.50M
Exchange
NMS
Currency
USD
52-Week Range
Related News
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA
Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target
Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.
Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target
Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.